Home-based administration of cancer immunotherapy (IO) is an emerging care model aimed at improving patient-centered care and accessibility. However, real-world evidence regarding its feasibility, safety, and patient experience remains limited.
Rubio et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: